Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRINZOLAMIDE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Open-angle glaucoma,Ocular hypertension
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
1 drop of 1% solution in the affected eye(s) twice daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized via hepatic cytochrome P450 isoenzymes, including CYP3A4, CYP2A6, CYP2C8, and CYP2C9, to its major metabolite N-desethylbrinzolamide.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~60% bound to plasma proteins (primarily albumin, also carbonic anhydrase in RBCs)
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.13–0.25 L/kg (confined primarily to plasma and RBCs; low Vd due to high tissue binding)
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Ophthalmic: systemic bioavailability ~10% (via corneal absorption); oral: not clinically used
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-60 m L/min, use with caution; no specific dose adjustment recommended but monitor for metabolic acidosis.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No specific adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Safety and efficacy not established in pediatric patients (no approved dosing).
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment required; use with caution due to increased risk of corneal edema and metabolic acidosis in elderly patients.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Sulfonamide allergy: can cause serious adverse reactions similar to systemic sulfonamides, including Stevens-Johnson syndrome and toxic epidermal necrolysis.,Corneal endothelial function: use with caution in patients with compromised corneas due to potential for edema.,Bacterial keratitis: risk from contaminated ophthalmic solutions.,Ocular effects: may cause blurred vision, eye discomfort, and other local reactions.,Systemic effects: possible metabolic acidosis, especially in patients with renal impairment or concurrent oral carbonic anhydrase inhibitors.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to brinzolamide or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min) or hyperchloremic acidosis due to risk of metabolic acidosis,Concomitant use with oral carbonic anhydrase inhibitors (additive systemic effects)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No direct food interactions. However, brinzolamide may cause metabolic acidosis, so avoid carbonic anhydrase inhibitors (e.g., acetazolamide) and limit sodium bicarbonate intake. No specific dietary restrictions.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenic effects unknown; second and third trimesters: possible fetal acidosis due to maternal carbonic anhydrase inhibition.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excretion in human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. Consider alternative therapy.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended. Consider that pregnancy-induced physiologic changes (increased Vd, renal clearance) may reduce drug exposure; monitor clinical response.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Brinzolamide is a carbonic anhydrase inhibitor used topically for ocular hypertension. It reduces intraocular pressure by decreasing aqueous humor secretion. Unlike systemic CAIs, it causes fewer systemic side effects but may still cause metabolic acidosis in susceptible patients. Avoid use in patients with sulfonamide allergy due to cross-sensitivity. Monitor corneal endothelial function in patients with compromised corneas. Shake suspension well before use.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Shake the bottle well before each use.,Instill one drop in the affected eye(s) three times daily.,Wash hands before and after administration.,Remove contact lenses before instilling and wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface.,Report any signs of allergy or severe eye discomfort.,May cause temporary blurred vision; avoid driving until clear.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Brinzolamide, a carbonic anhydrase inhibitor used for glaucoma, can reduce intraocular pressure and may cause systemic acidosis. Ketoconazole, an azole antifungal, inhibits CYP3A4 and can increase the systemic exposure of drugs metabolized by this enzyme. Although brinzolamide is primarily eliminated renally, co-administration may lead to additive metabolic acidosis, potentially enhancing ketoconazole's toxicity due to altered pH-dependent drug distribution and clearance."
"Olsalazine, a prodrug of mesalamine used for ulcerative colitis, can cause metabolic acidosis via carbonic anhydrase inhibition in the kidney. Brinzolamide, a topical carbonic anhydrase inhibitor for glaucoma, may additively reduce renal bicarbonate reabsorption, increasing the risk of hyperchloremic metabolic acidosis and electrolyte disturbances. Concurrent use may exacerbate acidosis, leading to symptoms like tachypnea, fatigue, and confusion."
"The combination of two carbonic anhydrase inhibitors, Brinzolamide (ophthalmic) and Diclofenamide (systemic), can lead to additive inhibition of carbonic anhydrase in renal tubules, resulting in enhanced systemic absorption and elevated plasma concentrations of Brinzolamide. This may cause severe metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and increased risk of sulfonamide-related adverse effects such as Stevens-Johnson syndrome. Patients may present with confusion, tachypnea, cardiac arrhythmias, or acute kidney injury."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRINZOLAMIDE vs ACTIQ, answered by our medical review team.
BRINZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRINZOLAMIDE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRINZOLAMIDE is: 1 drop of 1% solution in the affected eye(s) twice daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRINZOLAMIDE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRINZOLAMIDE is classified as Category A/B. Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy . ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.